Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyprexa Removal From Florida Medicaid Drug List Recommended By P&T Cmte

Executive Summary

Use of Lilly's antipsychoticZyprexa would require prior authorization under Florida's Medicaid program should the state approve recommendations by a pharmacy & therapeutics committee

You may also be interested in...



Lilly’s Zyprexa, Cymbalta Will Be Dropped From Florida Medicaid Drug List

Florida Medicaid will reconsider the status of GlaxoSmithKline's Paxil, Forest's Lexapro and Pfizer's Zoloft on the state's preferred drug list in September after awarding the antidepressants conditional placement on the PDL

Lilly’s Zyprexa, Cymbalta Will Be Dropped From Florida Medicaid Drug List

Florida Medicaid will reconsider the status of GlaxoSmithKline's Paxil, Forest's Lexapro and Pfizer's Zoloft on the state's preferred drug list in September after awarding the antidepressants conditional placement on the PDL

Neurontin Off-Label Use Needs Prior Authorization Under Fla. Medicaid Plan

Prior authorization for off-label use of Pfizer's Neurontin would save the Florida Medicaid program $7 mil., the FY 2004-2005 budget proposal states

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel